Research & Development
Investing in the future – led by science
The future of treatment for many of today’s diseases lies in uncovering disease mechanisms that are newly emerging or are still to be discovered. We believe the best way we can help patients is to focus on breakthrough science to discover disease mechanisms and develop novel, targeted therapies. This is at the heart of our business and our purpose as a company: to push the boundaries of science to deliver life-changing medicines.
We focus on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic Disease (CVRM) and Respiratory, while selectively pursuing promising therapies in Autoimmunity, Infection and Neuroscience.
Our science leverages our rare combination of capabilities in small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science. We build on these capabilities by collaborating with world-renowned scientists and academic institutions, and partner with like-minded, science-led companies.
In our research laboratories, and those of our partners, our unrelenting focus is on scientific quality, smart risk taking and good decision making. Only this single-mindedness will help us properly understand disease biology and deliver the next generation of differentiated medicines. It is why we believe our pipeline includes some of most exciting and innovative molecules in development across the industry, adding to the portfolio of important medicines we currently market.
As a global, science-led biopharmaceutical company delivering medicines to patients through innovative science and excellence in development and commercialisation, we are well-placed to turn innovative molecules into medicines that are life changing. We combine data, facts and the insights of patients, payers, regulators and physicians throughout the development process. We design studies that allow the impact and value of our molecules to be evaluated in clinical and real world settings. This ensures the medicines we bring to our customers are effective and well-tolerated, and that healthcare decision-makers have the information they need to make the best treatment choices for their patients.
Applications closed on 21 April 2018. Successful applicants will be notified at the end of October 2018.